Hit generation and exploration: Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 23, 2007, Pages 6567-6571

  Bavetsias, Vassilios ^a   Sun, Chongbo ^a   Bouloc, Nathalie ^a   Reynisson, Jóhannes ^a   Workman, Paul ^a   Linardopoulos, Spiros ^a   McDonald, Edward ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Aurora; Imidazo 4,5 b pyridines; Kinases

Indexed keywords

(2 (4 (6 CHLORO 2 (4 DIMETHYLAMINO)PHENYL) 3H IMIDAZO[4,5 B]PYRIDIN 7 YL)PIPERAZIN 1 YL) N (THIZOL 2 YL)ACETAMIDE; AURORA KINASE INHIBITOR; IMIDAZO[4,5 B]PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG INHIBITION; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

CELL PROLIFERATION; DRUG DESIGN; GROWTH INHIBITORS; HCT116 CELLS; HUMANS; IMIDAZOLES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PURINES; PYRIDINES;

EID: 35649014837     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.09.076     Document Type: Article

References (29)

1. Keen N., and Taylor S. Nat. Rev. Cancer 4 (2004) 927
2. Matthews N., Visintin C., Hartzoulakis B., Jarvis A., and Selwood D.L. Expert Rev. Anticancer Ther. 6 (2006) 109
3. Tanaka T., Kimura M., Matsunaga K., Fukada D., Mori H., and Okano Y. Cancer Res. 59 (1999) 2041
4. Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., Schryver B., Flanagan P., Clairvoyant F., Ginther C., Chan C.S.M., Novotny M., Slamon D.J., and Plowman G.D. EMBO J. 17 (1998) 3052
5. Chieffi P., Troncone G., Caleo A., Libertini S., Linardopoulos S., Tramontano D., and Portella G. J. Endocrinol. 181 (2004) 263
6. Gritsko T.M., Coppola D., Paciga J.E., Yang L., Sun M., Shelley S.A., Fiorica J.V., Nicosia S.V., and Cheng J.Q. Clin. Cancer Res. 9 (2003) 1420
7. Reichardt W., Jung V., Brunner C., Klein A., Wemmert S., Romeike B.F.M., Zang K.D., and Urbschat S. Oncol. Rep. 10 (2003) 1275
8. Ditchfield C., Johnson V.L., Tighe A., Ellston R., Haworth C., Johnson T., Mortlock A., Keen N., and Taylor S.S. J. Cell Biol. 161 (2003) 267
9. Harrington E.A., Bebbington D., Moore J., Rasmussen R.K., Ajose-Adeogun A.O., Nakayama T., Graham J.A., Demur C., Hercend T., Diu-Hercend A., Su M., Golec J.M.C., and Miller K.M. Nat. Med. 10 (2004) 262
10. Fancelli D., Berta D., Bindi S., Cameron A., Cappella P., Carpinelli P., Catana C., Forte B., Giordano P., Giorgini M.L., Mantegani S., Marsiglio A., Meroni M., Moll J., Pittala V., Roletto F., Severino D., Soncini C., Storici P., Tonani R., Varasi M., Vulpetti A., and Vianello P. J. Med. Chem. 48 (2005) 3080
11. Soncini C., Carpinelli P., Gianellini L., Fancelli D., Vianello P., Rusconi L., Storici P., Zugnoni P., Pesenti E., Croci V., Ceruti R., Giorgini M.L., Cappella P., Ballinari D., Sola F., Varasi M., Bravo R., and Moll J. Clin. Cancer Res. 12 (2006) 4080
12. Manfredi M.G., Ecsedy J.A., Meetze K.A., Balani S.K., Burenkova O., Chen W., Galvin K.M., Hoar K.M., Huck J.J., LeRoy P.J., Ray E.T., Sells T.B., Stringer B., Stroud S.G., Vos T.J., Weatherhead G.S., Wysong D.R., Zhang M., Bolen J.B., and Claiborne C.F. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 4106
13. Mortlock A.A., Foote K.M., Heron N.M., Jung F.H., Pasquet G., Lohmann J.-J.M., Warin N., Renaud F., De Savi C., Roberts N.J., Johnson T., Dousson C.B., Hill G.B., Perkins D., Hatter G., Wilkinson R.W., Wedge S.R., Heaton S.P., Odedra R., Keen N.J., Crafter C., Brown E., Thompson K., Brightwell S., Khatri L., Brady M.C., Kearney S., McKillop D., Rhead S., Parry T., and Green S. J. Med. Chem. 50 (2007) 2213
14. Sun C., Newbatt Y., Douglas L., Workman P., Aherne W., and Linardopoulos S. J. Biomol. Screen. 9 (2004) 391
15. Singh M.P., Joseph T., Kumar S., Bathini Y., and Lown J.W. Chem. Res. Toxicol. 5 (1992) 597
16. Minehan T.G., Gottwald K., and Dervan P.B. Helv. Chim. Acta 83 (2000) 2197
17. Dubey P.K., and Ratnam C.V. Indian J. Chem. 18B (1979) 428
18. For synthetic approaches to benzimidazoles and imidazopyridines also see. Singh M.P., Sasmal S., Lu W., and Chatterjee M.N. Synthesis (2000) 1380
19. Bavetsias, V.; McDonald, E.; Linardopoulos, S. Patent WO 2007/072017 A2, 2007.
20. Yang D., Fokas D., Li J., Yu L., and Baldino C.M. Synthesis (2005) 47
21. For clarity, imidazo[4,5-b]pyridines are represented in a single tautomeric form.
22. Cherry M., and Williams D.H. Curr. Med. Chem. 11 (2004) 663
23. Cheetham G.M.T., Knegtel R.M.A., Coll J.T., Benwick S.B., Swenson L., Weber P., Lippke J.A., and Austen D.A. J. Biol. Chem. 277 (2002) 42419
24. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. Nucleic Acids Res. 28 (2000) 235
25. 2,3-Diamino-4,5-dichloropyridine, required for the synthesis of 27, was prepared by reducing 2-amino-4,5-dichloro-3-nitropyridine as described in: Johanson, H.; Lawitz, K.; Nikitidis, G.; Sjo, P.; Storm, P. Patent WO 2004016611 A1. Likewise, 4-chloro-2,3-diaminopyridine, required for the synthesis of 29, was prepared from 2-amino-4-chloro-3-nitropyridine by applying the same methodology.
26. 50 values were determined using either the Flashplate assay as described in Ref. 14, or the Filterplate assay as described in Ref. 17. ATP concentration in the assay is 20 μM.
27. 3).
28. Inhibition of human liver CYP isozymes was assessed in human liver microsomes (pool of 50 individuals) as described in Ref. 27 with the following modifications: microsomal protein concentration 0.5 mg/ml, incubation time 10 min, mephenytoin as the CYP2C19 substrate and metabolite detection by LC-MS-MS ESI+ on a Shimadzu LC system connected to a QTRAP 4000 (Applied Biosystems).
29. Moreno-Farre J., Workman P., and Raynoud F.I. Austral-Asian J. Cancer 6 (2007) 55